Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)


 0.87 (2.26%)

Market Cap$5,395,412,963

10/09/15  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2015 Financial Results on October 29, 2015 10/08/15

Read more

Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-line Hodgkin Lymphoma 10/07/15

Read more


Third Quarter 2015 Financial Results Conference Call10/29/15 4:30 p.m. ETView eventSecond Quarter 2015 Financial Results Conference Call07/30/15 4:30 p.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources